ABBV•benzinga•
AbbVie Enters Obesity Market with ~$2.2B Gubra Deal To Develop Next-Gen Amylin Therapy, With $350M Upfront Payment
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga